MoonLake ImmunotherapeuticsMLTX
About: MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Employees: 100
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
141% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $8.78M
131% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 16
17% more funds holding
Funds holding: 115 [Q4 2024] → 134 (+19) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
5.98% less ownership
Funds ownership: 100.57% [Q4 2024] → 94.58% (-5.98%) [Q1 2025]
29% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 42
32% less capital invested
Capital invested by funds: $3.43B [Q4 2024] → $2.34B (-$1.1B) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Wolfe Research Andy Chen | 56%upside $61 | Outperform Upgraded | 19 May 2025 |
Needham Serge Belanger | 68%upside $66 | Buy Reiterated | 13 May 2025 |
RBC Capital Brian Abrahams | 71%upside $67 | Outperform Initiated | 18 Mar 2025 |
Goldman Sachs Richard Law | 86%upside $73 | Buy Maintained | 27 Feb 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 155%upside $100 | Buy Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 3 articles about MLTX published over the past 30 days









